Compass Therapeutics Inc.’s Post

Radiopharmaceuticals – Transforming Treatment Modality in Cancer 1️⃣ Many of the newer radiopharmaceuticals are being repurposed to carry more potent radioactive compounds used for nuclear imaging, the ones that could kill cancer cells instead of simply helping visualize them 2️⃣ The last few years have seen an explosion of research and clinical testing of new radiopharmaceuticals. Researchers are now designing and testing radiopharmaceuticals for a range of cancers such as melanoma, lung cancer, colorectal cancer, and leukemia 3️⃣ Radiopharmaceuticals is in the spotlight catalyzed by technical advances, and regulatory approvals. More than a dozen startups have pulled in sizable funding rounds from a range of biotech VC firms. We expect the deal activity to further pick up momentum ahead. #radiopharmaceuticals #radiationoncology #cancertherapy #oncology #cancermedicine #development #marketanalysis #marketresearch #marketaccess #pipeline #strategy #intelligence #competitiveintelligence #marketintelligence #eosintelligence #perspectives #leadership #innovation #lifesciences #lifesciencesindustry #biotech #biotechinnovation #biopharma #biopharmaceuticals Roche Novartis Bayer Bristol Myers Squibb ----------------------------------------------------------------------------------- Looking to monitor the competitive landscape in the rapidly evolving Oncology treatment landscape, including catalysts, financial metrics, partnerships, pricing and reimbursement? At EOS intelligence, we deliver reliable primary competitive insights that sets the stage for successful product launch and market access

Radiopharmaceuticals are on the rise

Radiopharmaceutical company Telix Pharmaceuticals Limited targets $202M IPO in the US. Amidst the growing interest in radiopharmaceuticals, Telix estimates that the net proceeds from the offering will be $183 million, potentially rising to $211 million if underwriters fully exercise their option to purchase additional shares. As reported by Lei Lei Wu, Australian biotech Telix Pharmaceuticals, which is already listed on the Australian Stock Exchange, intends to list on Nasdaq under the ticker symbol $TLX. Telix has two approved radioisotope diagnostics and is awaiting an FDA decision on two more. Additionally, the company is developing a range of experimental radiotherapies, including treatments for prostate cancer, kidney cancer, and glioblastoma, an aggressive brain cancer. Its leading prostate cancer drug candidate is in a Phase 3 trial, with interim data expected in the first half of 2025. Radio-imaging using targeted radiation relies heavily on digital data processing and input from highly trained technicians and radiologists to correctly interpret data. Telix uses AI technology to transform image analysis by improving the accuracy and speed of decision-making for clinicians by recognising complex patterns in large datasets and conducting predictive analysis. This Sunday I will share an expanded insight into what is happening in the booming radiopharmaceuticals market and unique challenges it faces, in this week's "Where Tech Meets Bio" newsletter. Join 6k+ email subscribers reading "Where Tech Meets Bio" every week! #radiopharmaceuticals #biopharmatrend #IPO #Nasdaq Image credit: International Atomic Energy Agency (IAEA)

With over 86 strategic deals over the past 5 years, radiopharmaceuticals are hot. Now the second-generation drugs like Xofigo (approved in 2013), Lutathera (approved in 2018) and Pluvicto (approved in 2022) prove to be commercially successful, the industry is witnessing a renaissance according to the news item featured in Nature's Biopharma Dealmakers: https://lnkd.in/gdXwHSkc The article underscores the potential of radiopharmaceuticals by addressing the ability to combine diagnostic and therapeutic properties, championing the 'see and treat' approach known as Theranostics. This paradigm shift holds immense promise for improving patient outcomes, optimizing treatment strategies and advancing precision-medicine approaches. As technology continues to mature, a surge in deal activities from pharmaceutical companies and increased venture capital investments are anticipated, further propelling innovation. At Minerva Imaging, we take pride in our longstanding commitment in the field, building on more than two decades of research within oncology and molecular imaging performed at the University of Copenhagen (Københavns Universitet) and Rigshospitalet, the National University Hospital of Denmark. Today, we offer on-site radiochemistry, in vitro and ex vivo assays, in vivo evaluation supporting biodistribution and efficacy, in-house dosimetry, and CDMO/CMC services. Contact us today to unlock the potential of your drug development program: https://lnkd.in/gyGpdVB #radiopapharmaceuticals #theranostics #diagnostics #therapeutics #oncolology

🌐 We are excited to share the insights from our latest 'Biosimilars in Oncology – Thematic Intelligence' report! The biosimilar market size in the 8MM was $4 billion in 2022 and is expected to achieve a CAGR of more than 9% during 2022-2029. The market growth has increased sharply in the last five years due to the launch of biosimilars such as bevacizumab, rituximab, and trastuzumab in the 8MM, as well as the high adoption of these products. 📈 Elevate your understanding of the market with our in-depth analysis report! #lifesciences #pharmaceuticals #biotechnology #oncology #biosimilars

𝐑𝐚𝐭𝐢𝐨 𝐓𝐡𝐞𝐫𝐚𝐩𝐞𝐮𝐭𝐢𝐜𝐬 𝐀𝐧𝐧𝐨𝐮𝐧𝐜𝐞𝐬 $𝟓𝟎𝐌 𝐒𝐞𝐫𝐢𝐞𝐬 𝐁 𝐅𝐢𝐧𝐚𝐧𝐜𝐢𝐧𝐠 𝐭𝐨 𝐀𝐝𝐯𝐚𝐧𝐜𝐞 𝐓𝐚𝐫𝐠𝐞𝐭𝐞𝐝 𝐑𝐚𝐝𝐢𝐨𝐭𝐡𝐞𝐫𝐚𝐩𝐢𝐞𝐬 𝐟𝐨𝐫 𝐂𝐚𝐧𝐜𝐞𝐫 𝐓𝐫𝐞𝐚𝐭𝐦𝐞𝐧𝐭 Ratio Therapeutics Inc. (Ratio) Ratio Therapeutics, a pharmaceutical company that employs a suite of innovative technologies to develop best-in-class radiopharmaceuticals for the treatment and monitoring of cancers, announces the close of its $50M Series B financing, bringing the total raised to date to over $90 million. The latest round witnessed continued participation from Series A leads Schusterman and Duquesne and welcomed among others PagsGroup, Bristol Myers Squibb and the Center for Technology Licensing at Cornell University. This financing will expand the applications of the company's proprietary technology platforms, Trillium™ and Macropa™, to develop novel best in class fit-for-purpose radiopharmaceuticals. Additionally, the funding will drive the clinical development of the company's fibroblast activation protein-alpha (FAP) targeted radiopharmaceutical therapeutic. "This funding advances Ratio's technology platforms and will help launch clinical trials for our FAP-targeted radiotherapeutic which aims to treat a broad array of solid-tumor cancers," said Dr. Jack Hoppin Jack Hoppin, Ratio's Chairman and Chief Executive Officer. "We are grateful to our investors for their confidence in our technology. We have filed two INDs and completed enrollment in both radiation dosimetry studies in support of two of our corporate partnerships. Now we have the backing to move our first therapeutic candidate into clinical trials by the end of this year." "The FAP-targeted therapeutic program has the potential to provide much needed treatment to patients with multiple types of cancer," said Dr. Mey Boukenna Mey Boukenna , M.D., Ph.D. of PagsGroup, the Boston-based family office of Stephen Pagliuca. "With Ratio's unique assets and technology, and Drs. Babich and Hoppin standing as pioneers in the radiopharmaceutical field, we believe they are very well positioned to advance novel radiopharmaceutical cancer treatments and diagnostics into the clinic." #clinicaltrials #healthcare #diagonstics #therapeutic #treatment #solidtumors #cancer #funding #investment

Roundup of the latest antibody pharma industry deals 👇   🤝 ONO PHARMACEUTICAL CO., LTD. partners with Epsilon Molecular Engineering Inc. (EME) for antibody drug discovery   💰 AbbVie offers potential $713M for OSE Immunotherapeutics’s antibody for the treatment of chronic inflammation   💉 Epsilogen Ltd and Lonza achieve the first large-scale GMP manufacturing of a therapeutic IgE antibody (MOv18, aimed to treat platinum-resistant ovarian cancer)   🎯 FogPharma raises $145M in Series E financing to target solid tumors with its Helicon peptides   🔎 Gilead Sciences and Merus N.V. enter collaboration with potential $1.5B deal to discover novel antibody-based trispecific T-cell engagers   #Biointron #Antibodies #Immunotherapy #PharmaNews #DrugDevelopment #DrugDiscovery #Oncology #Innovation #Networking #Healthcare

Exciting developments at the 42nd annual J.P. Morgan Healthcare Conference! GSK has joined the ranks of industry leaders in the dealmaking frenzy. Notably, J&J committed $2 billion to acquire Ambrx, specializing in antibody-drug conjugates for cancer. Merck followed suit with a $680 million investment in Harpoon Therapeutics for T-cell engagers in oncology. Meanwhile, Novartis made strategic moves, including a $250 million buyout of Calypso Biotech to enhance its presence in immune diseases. Additionally, two RNAi license deals with Shanghai Argo Biopharmaceutical are set to advance cardiovascular indications. The healthcare landscape is evolving, and it's inspiring to witness these impactful collaborations! #HealthcareInnovation #IndustryLeaders #DealMaking #JPMorganConference #lifescience

𝗧𝗮𝗿𝗴𝗲𝘁𝗲𝗱 𝗥𝗮𝗱𝗶𝗮𝘁𝗶𝗼𝗻 𝗧𝗵𝗲𝗿𝗮𝗽𝗶𝗲𝘀 (𝗧𝗥𝗧) represent an area of growing investment by the pharmaceutical industry. This blog explains how using clinical pharmacology best practices can refine TRT dose selection and enhance treatment outcomes. Read our latest insights:  https://ow.ly/5C4p50QZ5OB #CancerResearch #TargetedRadiationTherapy #CancerTreatment #Oncology #ClinicalTrials #FDAguidelines #EMAguidelines #ProjectOptimus #ModelingSimulation #PKdata #DoseSelection #ClinicalPharmacology

📣 Our collaborative work with HanX Biopharmaceutical, employing a unique and broad portfolio of preclinical modeling in support of HanX’s successful FDA Investigational New Drug application, has been published in Scientific Reports, a journal within the Nature Portfolio. The study demonstrated that HX009, an investigational “first-in-class” PD-1 x CD47 bispecific antibody, binds differentially to both PD-1 and CD47 with strong affinity to PD-1 but weakened affinity to CD47. This feature enables better targeting to the tumor microenvironment (TME) and minimizes potential hematological toxicity. In addition, HX009 exhibited enhanced T-cell activating capability over HX008, an approved and marketed anti-PD-1 monoclonal antibody in China. Read more in our press release! https://bit.ly/44kjDqD #CrownBioscienceNews #Biotech #Oncology #Lymphoma